A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: The role of a novel G796A mutation in exon 20 of EGFR

Hidetaka Uramoto, Takeshi Uchiumi, Hiroto Izumi, Kimitoshi Kohno, Tsunehiro Oyama, Kenji Sugio, Kosei Yasumoto

研究成果: Contribution to journalArticle査読

16 被引用数 (Scopus)

抄録

Subsets of non-small cell lung cancer (NSCLC) patients who carry activating somatic mutations of the epidermal growth factor receptor (EGFR) have demonstrated an increased probability of obtaining objective responses to the receptor tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib. However, a substantial proportion of the cases with somatic mutations, which suggest sensitivity to gefitinib, are primary resistant to it. A primary resistant case of lung adenocarcinoma that was found to carry both delE746-A750 and a G796A mutation in the EGFR is reported. In vitro, a stable clone of cells bearing the G796A mutation was approximately 50,000-fold less sensitive to gefitinib in comparison to cells carrying the delE746-A750 mutant EGFR. This study suggests that screening tumour samples for a range of EGFR mutations may improve our ability to identify the patients most likely to benefit from EFGR TKIs.

本文言語英語
ページ(範囲)2297-2303
ページ数7
ジャーナルAnticancer research
27
4 B
出版ステータス出版済み - 7 1 2007
外部発表はい

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

フィンガープリント 「A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: The role of a novel G796A mutation in exon 20 of EGFR」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル